Clinical efficacy of mucoactive therapy with 7% hypertonic saline in patients with acute bronchitis

Introduction. Respiratory viruses are the overwhelming etiological agents of acute bronchitis in adults. However, the routine management of such patients often includes the prescription of antibiotics. The primary treatment for acute bronchitis is the administration of mucoactive agents to liquefy and improve sputum flow.

The aim is to investigate the efficacy and safety of 7% hypertonic solution in patients with acute bronchitis.

Materials and methods. A total of 50 patients were enrolled, of whom 25 participants received Ingasalin® forte (7% hypertonic solution) and 25 patients formed a second control group in which participants received other drugs as mucoactive therapy (routine clinical practice).

Results. Severity of productive cough in Group 1 patients equaled 2,24 ± 0,4 points, in Group 2 – 2,4 ± 0,5 points. On the 4th day there was a significant reduction in the severity of both daytime and nighttime cough in the vast majority of patients. At the same time, severity of daytime cough on the 4th day of treatment in Group 1 was equal to 1,36 ± 0,5, and in Group 2 – to 1,7 ± 0,5. During the same period, the number of AB patients with a significant reduction in cough severity in group 1 was 16 (64%), while in group 2–8 (32%).

Conclusion. Thus, the use of 7% hypertonic solution was accompanied by a good effect in the form of a pronounced cough regression in patients with AB.

1. Chuchalin A.G. (ed.). Pulmonology. National leadership. Short edition. Moscow: GEOTAR-Media; 2016. 800 p. (In Russ.)

2. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347–382. https://doi.org/10.1086/313954.

3. Wenzel R.P., Fowler A.A. 3rd. Clinical practice. Acute bronchitis. N Engl J Med. 2006;355(20):2125–2130. https://doi.org/10.1056/NEJMcp061493.

4. Albert R.H. Diagnosis and treatment of acute bronchitis. Am Fam Physician. 2010;82(11):1345–1350. Available at: https://www.aafp.org/pubs/afp/issues/2010/1201/p1345.html.

5. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M. et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17(Suppl. 6):E1–59. https://doi.org/10.1111/j.1469-0691.2011.03672.x.

6. Zaitsev A.A., Kulagina I.Ts. Acute bronchitis. Farmateka. 2015;(14):89–95. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/31936.

7. Falsey A.R., Criddle M.M., Kolassa J.E., McCann R.M., Brower C.A., Hall W.J. Evaluation of a handwashing intervention to reduce respiratory illness rates in senior day-care centers. Infect Control Hosp Epidemiol. 1999;20(3):200–202. https://doi.org/10.1086/501612.

8. Smucny J., Fahey T., Becker L., Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004;(4):CD000245. https://doi.org/10.1002/14651858.CD000245.pub2.

9. Gonzales R., Bartlett J.G., Besser R.E., Cooper R.J., Hickner J.M., Hoffman J.R., Sande M.A. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134(6):521–529. https://doi.org/10.7326/0003-4819-134-6-200103200-00021.

10. Irwin R.S., Baumann M.H., Bolser D.C., Boulet L.P., Braman S.S., Brightling C.E. et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(Suppl. 1):1S–23S. https://doi.org/10.1378/chest.129.1_suppl.1S.

11. Tackett K.L., Atkins A. Evidence-based acute bronchitis therapy. J Pharm Pract. 2012;25(6):586–590. https://doi.org/10.1177/0897190012460826.

12. Muñoz F., Carvalho M.S. Efecto del tiempo de exposición a PM(10) en las urgencias por bronquitis aguda. Cad Saude Publica. 2009;25(3):529–539. https://doi.org/10.1590/s0102-311x2009000300008.

13. Ott S.R., Rohde G., Lepper P.M., Hauptmeier B., Bals R., Pletz M.W. et al. Die Rolle von Viren bei tiefen Atemwegsinfektionen des Erwachsenen. Teil 2: Akute Bronchitis, exazerbierte COPD, Pneumonie und Influenza. Pneumologie. 2010;64(1):18–27. https://doi.org/10.1055/s-0029-1215197.

14. Wadowsky R.M., Castilla E.A., Laus S., Kozy A., Atchison R.W., Kingsley L.A. et al. Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. J Clin Microbiol. 2002;40(2):637–640. https://doi.org/10.1128/JCM.40.2.637-640.2002.

15. Riffelmann M., Littmann M., Hülsse C., O’Brien J., Wirsing von König C.H. Pertussis bei Erwachsenen: Häufigkeit, Symptome und Kosten. Dtsch Med Wochenschr. 2006;131(50):2829–2834. https://doi.org/10.1055/s-2006-957208.

16. Zaytsev A.A., Ovchinnikov Yu.V., Kondrateva T.V. Biological markers of inflammation in community-acquired pneumonia. Consilium Medicum. 2014;16(11):36–41. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/94153.

17. Zaitsev A.A. Directions of pharmacotherapy and prevention of acute respiratory viral infections. RMJ. 2009;17(23):1525–1529. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Napravleniya_farmakoterapii_i_profilaktiki_ostryh_respiratornyh_virusnyh_infekciy/.

18. Zaitsev A.A., Okovity S.V., Kryukov E.V. Cough. Moscow: Main Military Clinical Hospital named after N.N. Burdenko; 2015. 59 p. (In Russ.)

19. Reeves E.P., Williamson M., O’Neill S.J., Greally P., McElvaney N.G. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011;183(11):1517–1523. https://doi.org/10.1164/rccm.201101-0072OC.

20. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105(12):1831–1835. https://doi.org/10.1016/j.rmed.2011.07.019.

21. Titova O.N., Kuzubova N.A., Skliarova D.B., Aleksandrov A.L., Egorova N.V. The effectiveness of combination of 7% hypertonic saline and 0.1% natrii hyaluronas in patients with chronic obstructive pulmonary disease who have suffered a new coronavirus infection. Meditsinskiy Sovet. 2021;(16):85–91. (In Russ.) https://doi.org/10.21518/2079-701X-2021-16-85-91.

22. Denisova A.R., Kolosova N.G., Grebeneva I.V., Denisova V.D., Glukhova M.V., Lurie E.V. Application of hypertonic saline in children with acute bronchitis. Meditsinskiy Sovet. 2021;(17):78–84. (In Russ.) https://doi.org/10.21518/2079-701X-2021-17-78-84.